InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients

the LIAISON study protocol

Fulvio Braido, Guy Brusselle, Eleonora Ingrassia, Gabriele Nicolini, David Price, Nicolas Roche, Joan B Soriano, Heinrich Worth

Research output: Contribution to journalArticle

5 Citations (Scopus)
4 Downloads (Pure)

Abstract

Background According to international guidelines, the goal of asthma management is to achieve and maintain control of the disease, which can be assessed using composite measures. Prospective studies are required to determine how these measures are associated with asthma outcomes and/or future risk. The ‘InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol (LIAISON)’ observational study has been designed to evaluate asthma control and its determinants, including components of asthma management. Methods/design The LIAISON study will be conducted in 12 European countries and comprises a cross-sectional phase and a 12-month prospective phase. Both phases will aim at assessing asthma control (six-item Asthma Control Questionnaire, ACQ), asthma-related quality of life (Mini Asthma Quality of Life Questionnaire, Mini-AQLQ), risk of non-adherence to treatment (four-item Morisky Medication Adherence Scale, MMAS-4), potential reasons for poor control, treatment strategies and associated healthcare costs. The cross-sectional phase will recruit > 8,000 adult patients diagnosed with asthma for at least 6 months and receiving the same asthma treatment in the 4 weeks before enrolment. The prospective phase will include all patients with uncontrolled/poorly controlled asthma at the initial visit to assess the proportion reaching control during follow-up and to examine predictors of future risk. Visits will take place after 3, 6 and 12 months. Discussion The LIAISON study will provide important information on the prevalence of asthma control and on the quality of life in a broad spectrum of real-life patient populations from different European countries and will also contribute to evaluate differences in management strategies and their impact on healthcare costs over 12 months of observation.
Original languageEnglish
Article number18
JournalBMC Pulmonary Medicine
Volume13
DOIs
Publication statusPublished - 25 Mar 2013

Fingerprint

Asthma
Quality of Life
Health Care Costs
Medication Adherence
Observational Studies
Therapeutics
Observation
Prospective Studies
Guidelines

Keywords

  • asthma control
  • ACQ
  • LIAISON
  • observational study
  • qulaity of life
  • patient reported outcomes

Cite this

InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients : the LIAISON study protocol. / Braido, Fulvio; Brusselle, Guy ; Ingrassia, Eleonora ; Nicolini, Gabriele ; Price, David; Roche, Nicolas; Soriano, Joan B; Worth, Heinrich .

In: BMC Pulmonary Medicine, Vol. 13, 18, 25.03.2013.

Research output: Contribution to journalArticle

Braido, Fulvio ; Brusselle, Guy ; Ingrassia, Eleonora ; Nicolini, Gabriele ; Price, David ; Roche, Nicolas ; Soriano, Joan B ; Worth, Heinrich . / InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients : the LIAISON study protocol. In: BMC Pulmonary Medicine. 2013 ; Vol. 13.
@article{256aaaf3094240f1aaa66b326f7bf03b,
title = "InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients: the LIAISON study protocol",
abstract = "Background According to international guidelines, the goal of asthma management is to achieve and maintain control of the disease, which can be assessed using composite measures. Prospective studies are required to determine how these measures are associated with asthma outcomes and/or future risk. The ‘InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol (LIAISON)’ observational study has been designed to evaluate asthma control and its determinants, including components of asthma management. Methods/design The LIAISON study will be conducted in 12 European countries and comprises a cross-sectional phase and a 12-month prospective phase. Both phases will aim at assessing asthma control (six-item Asthma Control Questionnaire, ACQ), asthma-related quality of life (Mini Asthma Quality of Life Questionnaire, Mini-AQLQ), risk of non-adherence to treatment (four-item Morisky Medication Adherence Scale, MMAS-4), potential reasons for poor control, treatment strategies and associated healthcare costs. The cross-sectional phase will recruit > 8,000 adult patients diagnosed with asthma for at least 6 months and receiving the same asthma treatment in the 4 weeks before enrolment. The prospective phase will include all patients with uncontrolled/poorly controlled asthma at the initial visit to assess the proportion reaching control during follow-up and to examine predictors of future risk. Visits will take place after 3, 6 and 12 months. Discussion The LIAISON study will provide important information on the prevalence of asthma control and on the quality of life in a broad spectrum of real-life patient populations from different European countries and will also contribute to evaluate differences in management strategies and their impact on healthcare costs over 12 months of observation.",
keywords = "asthma control, ACQ, LIAISON, observational study, qulaity of life, patient reported outcomes",
author = "Fulvio Braido and Guy Brusselle and Eleonora Ingrassia and Gabriele Nicolini and David Price and Nicolas Roche and Soriano, {Joan B} and Heinrich Worth",
note = "The study is funded by Chiesi Farmaceutici S.p.A., Parma, Italy",
year = "2013",
month = "3",
day = "25",
doi = "10.1186/1471-2466-13-18",
language = "English",
volume = "13",
journal = "BMC Pulmonary Medicine",
issn = "1471-2466",
publisher = "BioMed Central",

}

TY - JOUR

T1 - InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol in European adult patients

T2 - the LIAISON study protocol

AU - Braido, Fulvio

AU - Brusselle, Guy

AU - Ingrassia, Eleonora

AU - Nicolini, Gabriele

AU - Price, David

AU - Roche, Nicolas

AU - Soriano, Joan B

AU - Worth, Heinrich

N1 - The study is funded by Chiesi Farmaceutici S.p.A., Parma, Italy

PY - 2013/3/25

Y1 - 2013/3/25

N2 - Background According to international guidelines, the goal of asthma management is to achieve and maintain control of the disease, which can be assessed using composite measures. Prospective studies are required to determine how these measures are associated with asthma outcomes and/or future risk. The ‘InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol (LIAISON)’ observational study has been designed to evaluate asthma control and its determinants, including components of asthma management. Methods/design The LIAISON study will be conducted in 12 European countries and comprises a cross-sectional phase and a 12-month prospective phase. Both phases will aim at assessing asthma control (six-item Asthma Control Questionnaire, ACQ), asthma-related quality of life (Mini Asthma Quality of Life Questionnaire, Mini-AQLQ), risk of non-adherence to treatment (four-item Morisky Medication Adherence Scale, MMAS-4), potential reasons for poor control, treatment strategies and associated healthcare costs. The cross-sectional phase will recruit > 8,000 adult patients diagnosed with asthma for at least 6 months and receiving the same asthma treatment in the 4 weeks before enrolment. The prospective phase will include all patients with uncontrolled/poorly controlled asthma at the initial visit to assess the proportion reaching control during follow-up and to examine predictors of future risk. Visits will take place after 3, 6 and 12 months. Discussion The LIAISON study will provide important information on the prevalence of asthma control and on the quality of life in a broad spectrum of real-life patient populations from different European countries and will also contribute to evaluate differences in management strategies and their impact on healthcare costs over 12 months of observation.

AB - Background According to international guidelines, the goal of asthma management is to achieve and maintain control of the disease, which can be assessed using composite measures. Prospective studies are required to determine how these measures are associated with asthma outcomes and/or future risk. The ‘InternationaL cross-sectIonAl and longItudinal assessment on aSthma cONtrol (LIAISON)’ observational study has been designed to evaluate asthma control and its determinants, including components of asthma management. Methods/design The LIAISON study will be conducted in 12 European countries and comprises a cross-sectional phase and a 12-month prospective phase. Both phases will aim at assessing asthma control (six-item Asthma Control Questionnaire, ACQ), asthma-related quality of life (Mini Asthma Quality of Life Questionnaire, Mini-AQLQ), risk of non-adherence to treatment (four-item Morisky Medication Adherence Scale, MMAS-4), potential reasons for poor control, treatment strategies and associated healthcare costs. The cross-sectional phase will recruit > 8,000 adult patients diagnosed with asthma for at least 6 months and receiving the same asthma treatment in the 4 weeks before enrolment. The prospective phase will include all patients with uncontrolled/poorly controlled asthma at the initial visit to assess the proportion reaching control during follow-up and to examine predictors of future risk. Visits will take place after 3, 6 and 12 months. Discussion The LIAISON study will provide important information on the prevalence of asthma control and on the quality of life in a broad spectrum of real-life patient populations from different European countries and will also contribute to evaluate differences in management strategies and their impact on healthcare costs over 12 months of observation.

KW - asthma control

KW - ACQ

KW - LIAISON

KW - observational study

KW - qulaity of life

KW - patient reported outcomes

U2 - 10.1186/1471-2466-13-18

DO - 10.1186/1471-2466-13-18

M3 - Article

VL - 13

JO - BMC Pulmonary Medicine

JF - BMC Pulmonary Medicine

SN - 1471-2466

M1 - 18

ER -